ractopamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics | 5611 | 97825-25-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Veterinary growth stimulant
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
| CHEBI has role | CHEBI:82655 | animal growth promotants |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | To increase rate of weight gain | Indication |
| Cattle | To improve feed efficiency | Indication |
| Swine | To increase rate of weight gain | Indication |
| Swine | To improve feed efficiency | Indication |
| Swine | Increases carcass leanness | Indication |
| Turkeys | To increase rate of weight gain | Indication |
| Turkeys | To improve feed efficiency | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Paylean 45, Paylean 9 | Elanco US Inc. | 1 |
| Paylean/Tylan | Elanco US Inc. | 2 |
| Optaflexx 45 | Elanco US Inc. | 1 |
| Optaflexx and Rumensin and Tylan | Elanco US Inc. | 3 |
| Optaflexx plus Rumensin | Elanco US Inc. | 2 |
| Optaflexx and Rumensin and Tylanand MGA | Elanco US Inc. | 4 |
| Optaflexx / Rumensin / MGA | Elanco US Inc. | 3 |
| Topmax 9 | Elanco US Inc. | 1 |
| Topmax plus Coban | Elanco US Inc. | 2 |
| Heifermax / Optaflexx / Rumensin / Tylan | Elanco US Inc. | 4 |
| Heifermax 500/Optaflexx/Rumensin | Elanco US Inc. | 3 |
| Paylean plus Tylovet | Huvepharma EOOD | 2 |
| Engain 9 and Engain 45 | Zoetis Inc. | 1 |
| Actogain 45 | Zoetis Inc. | 1 |
| Engain plus Tylan | Zoetis Inc. | 2 |
| Actogain 45 plus Rumensin | Zoetis Inc. | 2 |
| Actogain 45/Rumensin/MGA | Zoetis Inc. | 3 |
| Actogain 45/Rumensin/Tylan | Zoetis Inc. | 3 |
| Actogain 45/Rumensin/Tylan/MGA | Zoetis Inc. | 4 |
| Optaflexx 45/Rumensin/Tylovet 100 | Huvepharma EOOD | 3 |
| Optaflexx 45/Rumensin/Tylovet 100/MGA | Huvepharma EOOD | 4 |
| Actogain 45/Rumensin/Tylovet 100/MGA | Zoetis Inc. | 4 |
| Engain plus Tylovet 100 | Zoetis Inc. | 2 |
| Actogain 45/Rumensin/Tylovet 100 | Zoetis Inc. | 3 |
| Optaflexxand Monovet and Tylovet | Huvepharma EOOD | 3 |
| Actogain and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Optaflexxand Monovet and Tylan | Huvepharma EOOD | 3 |
| Actogain and Monovet and Tylan | Huvepharma EOOD | 3 |
| Optaflexx and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| Actogain and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| Optaflexx and Monovet and Tylan and MGA | Huvepharma EOOD | 4 |
| Actogain and Monovet and Tylan and MGA | Huvepharma EOOD | 4 |
| Actogain and Monovet and MGA | Huvepharma EOOD | 3 |
| Actogain and Monovet | Huvepharma EOOD | 2 |
| Optigrid and Monovet | Huvepharma EOOD | 2 |
| Optigrid and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Optigrid and Monovet and MGA | Huvepharma EOOD | 3 |
| Optigrid and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| Optigrid 45 | Huvepharma EOOD | 1 |
| Optigrid and Monovet and CycleGuard | Huvepharma EOOD | 3 |
| Optigrid and Monovet and Tylovet and CycleGuard | Huvepharma EOOD | 4 |
| RAC 45 CATTLE | Virbac AH Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | AGONIST | Ki | 6.74 | IUPHAR | ||||
| Beta-2 adrenergic receptor | GPCR | AGONIST | Ki | 6.74 | IUPHAR | ||||
| Trace amine-associated receptor 1 | GPCR | AGONIST | EC50 | 4.80 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| CHEBI:82644 | CHEBI |
| CHEMBL509336 | ChEMBL_ID |
| C060897 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10455 | IUPHAR_LIGAND_ID |
| DB11541 | DRUGBANK_ID |
| C0072954 | UMLSCUI |
| CHEMBL2105358 | ChEMBL_ID |
| 5850 | INN_ID |
| 90274-24-1 | SECONDARY_CAS_RN |
| D05691 | KEGG_DRUG |
| 56052 | PUBCHEM_CID |
| 1311676 | RXNORM |
| 57370OZ3P1 | UNII |
Pharmaceutical products:
None